They set up a policy where compounders could work around FDA approval guidelines in cases of shortages. But right now, there is no shortage of GLP-1 medications, and because companies like Eli Lilly and Novo Nordisk have patents, patients are likely years away from FDA-approved generics
Limited preclinical research has explored potential interactions between GLP-1 signaling and stress hormone pathways
Some evidence suggests semaglutide may offer cardiovascular benefits, such as reducing the risk of heart attack and stroke in people with diabetes, but individual reactions vary
As the healthcare industry adapts to the evolving needs of diabetic and obese patients, the demand for GLP-1 receptor agonists that offer a range of therapeutic options and flexible dosing schedules is expected to drive market growth further
It gets like, just like left out because, you know, we're going to sensationalize everything else